In the field of pharmaceutical intellectual property, the patent term extension (PTE) system for pharmaceuticals is a key incentive mechanism for medical innovation in China. Having been implemented for a relatively short time, it boasts only a small number of approved cases. Each successful approval sets a highly valuable benchmark for the industry. Recently, Zhifan IP Attorneys achieved a major milestone. The invention patent titled Levornidazole Phosphate Ester, Its Preparation Method and Application (Patent No.: 200610166893.2) for Huachuang Synthetic Pharmaceutical Co., Ltd., represented by our firm, has passed the examination of the National Intellectual Property Administration (CNIPA) and obtained the official approval for pharmaceutical patent term extension. This marks another exemplary successful case since the implementation of China’s pharmaceutical PTE regime.

The patent has been granted a total patent term extension of 1,826 days. Its original expiration date was December 15, 2026, and the valid term of the patent is now extended to December 15, 2031. The corresponding marketed drug for this extension is Levornidazole Phosphate Ester Disodium for Injection (National Medical Product Approval No.: H20210018). During the extended term, the scope of patent protection is strictly limited to this drug and its approved indications, fully complying with relevant national regulations on pharmaceutical patent term extension. The approval procedure is standard and the result is legally valid. In accordance with official requirements, the patentee has clarified the rules for annual fee payment to ensure the full implementation of the extended patent rights.

Throughout the case handling process, our project team addressed core examination difficulties and inquiries. Drawing on profound practical expertise in pharmaceutical intellectual property, we conducted comprehensive explanations and responsive arguments. We accurately defined the scope of patent protection in line with the Patent Law of the People's Republic of China and its implementing rules, and responded point by point to official examination opinions, ultimately securing the patent term extension approval.

Case Value: A Rare Approved Case Serving as a Practical Industry Reference

Developing an innovative drug, from research and development and clinical trials to official marketing approval, typically takes over a decade and requires massive capital investment. The lengthy review and approval process greatly erodes the statutory term of invention patents and dampens pharmaceutical enterprises’ enthusiasm for innovation — a long-standing challenge facing the pharmaceutical industry.

The pharmaceutical patent term extension system is designed to compensate for the patent time consumed during the marketing review and approval of new drugs. It safeguards the innovation returns of original drug developers and fosters a sound industrial ecosystem of "R&D – Launch – Profit – Further R&D".

In the initial stage of implementation, the system adopts stringent examination standards and strict technical definition requirements. It sets high thresholds for full-spectrum services including patent portfolio planning, claim drafting, evidence collation and application procedure management, resulting in very few successful approvals nationwide to date.

The smooth approval of this project fully demonstrates our comprehensive service capabilities in pharmaceutical patents:

• 
  

• Accurate technical definition: We conducted in-depth analysis of the pharmaceutical technical solutions, accurately established the correlation between the active pharmaceutical ingredients, production processes and patent claims, and clarified technical boundaries to pass core official verification.

• 
  

• Full-process professional management: We strictly followed all regulations of the CNIPA throughout the whole procedure, including application submission, document preparation, response to examination opinions and follow-up work, to eliminate potential application risks.

• 
  

• In-depth mastery of industry rules: We have a thorough understanding of the examination logic, scope restrictions and term requirements for pharmaceutical patent term extension stipulated in the Patent Law and its supporting rules. Leveraging rich practical experience, we successfully overcame various difficulties in the application.

As one of the few successful pharmaceutical PTE cases in China, this approval not only protects the client’s legitimate rights and interests, extends the market exclusivity period of its core pharmaceutical patent and offsets R&D costs, but also provides actionable references on application strategies, patent portfolio planning and procedural operations for pharmaceutical enterprises. We help more innovative pharmaceutical companies fully leverage the benefits of the pharmaceutical patent term extension policy.

Popular Science: A Complete Guide to Pharmaceutical Patent Term Extension

Many practitioners in the pharmaceutical industry wonder what pharmaceutical patent term extension is and what tangible benefits it can bring to drug developers. We hereby offer a concise interpretation based on current Chinese laws and regulations.

Pursuant to Paragraph 3 of Article 42 of the Patent Law of the People's Republic of China, pharmaceutical patent term extension is an exclusive right launched by the state for invention patents relating to innovative drugs and legally modified new drugs marketed in China. It aims to compensate for the patent time occupied by the review and approval of new drugs for marketing.

• 
  

• Eligible Subjects: Only patents covering active pharmaceutical ingredients, preparation methods and medical uses of new drugs are applicable.

• Core Rules: The maximum extension term for a single patent shall not exceed 5 years, and the total valid protection term of a new drug patent after marketing shall not exceed 14 years. This dual regulation strikes a balance between the innovation gains of pharmaceutical enterprises and public access to medicines.

• Core Functions: It offsets the loss of patent term caused by prolonged drug approval procedures, extends the legal protection period of core technologies, enhances the market competitiveness of original drugs, encourages continuous investment in new drug R&D, and facilitates China’s transformation from a major generic drug producer to a powerhouse of innovative pharmaceuticals.

Professional Empowerment to Secure Sustainable Development of Medical Innovation

Pharmaceutical intellectual property portfolio management runs through the entire lifecycle of drugs, covering R&D, clinical trials, marketing and rights enforcement. As a core means to extend intellectual property rights in the later stage, pharmaceutical patent term extension is an indispensable part of the intellectual property strategy for innovative pharmaceutical enterprises.

With years of dedication to the intellectual property sector, Zhifan IP Attorneys has accumulated extensive practical experience in pharmaceutical and chemical patent prosecution, portfolio planning, infringement defense, patent term extension and patent operation.

Going forward, we will continue to rely on our experienced attorney team, in-depth interpretation of policies and regulations, and rich project expertise to provide one-stop and customized intellectual property solutions for pharmaceutical enterprises. We help clients maximize patent value, build solid technical barriers and capture policy dividends. With professional IP services, we protect every achievement in medical innovation and work together to drive the high-quality development of China’s pharmaceutical industry.

Should you have any inquiries regarding pharmaceutical patent term extension application, pharmaceutical patent portfolio planning, response to patent examination opinions and other related services, please feel free to contact us.